Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer

Not Applicable

Completed

Conditions: Primary Peritoneal Carcinoma
Epithelial Ovarian Cancer
Fallopian Tube Cancer

Interventions: Procedure: Acute Normovolemic Hemodilution

First Posted Date: 2011-09-28

Last Posted Date: 2019-07-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 52

Registration Number: NCT01442051

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States

and more 1 locations

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

Phase 2

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Biological: Ofatumumab (This arm is closed)
Other: Ofatumumab + Bendamustine

First Posted Date: 2011-09-21

Last Posted Date: 2025-02-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT01437709

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 3 locations

Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Completed

Conditions: Cancer

Interventions: Behavioral: questionnaire administration followed by cognitive interviews

First Posted Date: 2011-09-19

Last Posted Date: 2017-05-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 112

Registration Number: NCT01436240

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Ralph Lauren Center for Cancer Care and Prevention, New York, New York, United States

and more 3 locations

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Phase 1

Active, not recruiting

Conditions: Acute Lymphocytic Leukemia
Lymphoma

Interventions: Biological: Biological/Genetically Modified T cells
Drug: Cyclophosphamide-based chemotherapy

First Posted Date: 2011-09-08

Last Posted Date: 2025-06-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 19

Registration Number: NCT01430390

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases

Completed

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor
Secondary Malignant Neoplasm of Liver

Interventions: Other: magnetic resonance imaging (MRI)

First Posted Date: 2011-08-26

Last Posted Date: 2023-01-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT01423734

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Phase 1

Completed

Conditions: Neuroblastoma

Interventions: Biological: Humanized 3F8 Monoclonal Antibody (Hu3F8)

First Posted Date: 2011-08-18

Last Posted Date: 2023-08-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 68

Registration Number: NCT01419834

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Phase 1

Terminated

Conditions: Leiomyosarcoma
Malignant Peripheral Nerve Sheath Tumor
Histiocytoma/Undifferentiated Pleomorphic Sarcoma
Sarcoma
Malignant Fibrous

Interventions: Drug: Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination

First Posted Date: 2011-08-16

Last Posted Date: 2018-01-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 5

Registration Number: NCT01418001

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
UCLA, Los Angeles, California, United States

and more 1 locations

Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: cyclophosphamide
Biological: modified T cells

First Posted Date: 2011-08-15

Last Posted Date: 2019-01-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 13

Registration Number: NCT01416974

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant

Not Applicable

Completed

Conditions: Multiple Myeloma

Interventions: Procedure: Fractionated Stem Cell Infusions

First Posted Date: 2011-08-12

Last Posted Date: 2016-04-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT01416246

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Measuring Patient Expectations for Thyroid Surgery

Active, not recruiting

Conditions: Thyroid Cancer

Interventions: Behavioral: patient interviews
Behavioral: CITSAV survey

First Posted Date: 2011-08-09

Last Posted Date: 2023-10-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 138

Registration Number: NCT01412762

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy